D-Allulose: A Review of Research Progress on Physiological Functions and Enzymatic Biotransformation

If you’re weighing D-allulose for a product launch, start with the peer-reviewed map. The paper appears in Foods, and the DOI is 10.3390/foods10092186. It compiles what formulators and ingredient buyers actually need to know: how D-allulose acts in the body, how it can be made, and what regulatory status it holds.

Why this review matters

D-allulose keeps showing up in formulation conversations. This review explains why. The authors state plainly that D-allulose has significant application value as a sugar substitute. It works as a food ingredient and as a dietary supplement. The paper also pulls together evidence for physiological effects that go beyond sweetness.

That distinction matters. You are not just buying a sweetener. You’re considering a molecule with documented effects on insulin resistance, anti-obesity, and glucolipid metabolism. For anyone in product development, that changes the conversation with R&D and marketing.

Background

In the United States, D-allulose has received FDA GRAS status. Regulators have approved it for use in a range of foods and dietary supplements. That is not a niche detail. GRAS status opens the door for commercial use without the delay of a full food additive petition.

The review places D-allulose in the context of ongoing efforts to reduce sugar and calories. It also points to the production side of the story. D-allulose is made through enzyme-based conversion. That is why the review spends real time on enzymatic biotransformation technology and production processes.

What the study did

The authors did not run a new clinical trial. They reviewed the existing literature and organized it around three questions. First, what does D-allulose do physiologically? Second, which enzymes can convert other sugars into D-allulose? Third, what production processes are realistic for commercial supply?

That structure is useful for buyers. It separates the science of “why” from the engineering of “how.” Both need to be true for D-allulose to work in your product.

Key findings

The core findings follow the paper’s three-part structure. D-allulose appears in the literature as a sugar substitute with more than one benefit. It has shown potential for improving insulin resistance, supporting anti-obesity efforts, and regulating glucolipid metabolism.

Production is equally important. The review highlights enzymatic biotransformation as the central route for making D-allulose. This is not a minor processing detail. Enzyme choice, conversion efficiency, and downstream purification determine whether the ingredient is cost-effective.

Area	What the review covers
Physiological function	Improving insulin resistance, anti-obesity, regulating glucolipid metabolism
Regulatory status	FDA GRAS; approved as an ingredient in multiple foods and dietary supplements
Production	Enzymatic biotransformation technology and production process
Application	Food ingredient and dietary supplement use

The paper itself is published in Foods, volume 10, article 2186. That gives you a citable reference when your team asks where this information came from.

What it means for manufacturers

For formulators, D-allulose offers a functional edge over a simple bulk sweetener. It may help address insulin response and weight management concerns. That is worth testing in your specific system.

For ingredient buyers, the production angle matters more than it might seem. D-allulose availability depends on enzymatic biotransformation. If a supplier cannot talk clearly about their enzyme process and GRAS compliance, treat that as a red flag. Ask for documentation. The regulatory path is clear, but not every supplier has the same process rigor.

The review also suggests that D-allulose should not be framed only as “sugar minus calories.” Its physiological functions are part of the value proposition. That affects how you position the finished product and what claims you can support.

Questions you might ask

Is D-allulose approved in the United States?
Yes. According to the review, D-allulose has received FDA GRAS status and is approved as an ingredient in many foods and dietary supplements.

Does D-allulose only replace sugar in recipes?
No. Beyond its role as a sugar substitute, the review covers effects on insulin resistance, anti-obesity, and glucolipid metabolism.

Why does enzymatic biotransformation matter?
Because D-allulose is made through enzyme-based conversion. The review treats biotransformation as a central part of the production process, so it directly affects supply and cost.

If you are evaluating D-allulose, this review gives you a firm foundation. It covers the regulatory status, the physiological evidence, and the production technology in one place. Read it with your application in mind, and you will have a clearer sense of where this sweetener can fit.